Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
81927-0105-01 81927-0105 Thiotepa TEPYLUTE 10.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intravenous Jan 1, 2025 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
82143-0001-01 82143-0001 Bevacizumab Avzivi 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan 1, 2025 In Use
83831-0131-01 83831-0131 Pemetrexed AXTLE 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
69448-0016-11 69448-0016 Trastuzumab-strf HERCESSI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan 1, 2025 In Use
82143-0002-01 82143-0002 Bevacizumab-tnjn Avzivi 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan 1, 2025 In Use
83831-0132-01 83831-0132 Pemetrexed AXTLE 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
00009-0112-05 00009-0112 Irinotecan hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec 30, 2024 In Use
00009-7529-10 00009-7529 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec 30, 2024 In Use
80425-0469-01 80425-0469 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 29, 2024 In Use
80425-0473-01 80425-0473 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 29, 2024 In Use
70436-0119-80 70436-0119 Leucovorin calcium Leucovorin Calcium 350.0 mg/1 Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Dec 27, 2024 In Use
70518-4243-00 70518-4243 PREDNISONE PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec 20, 2024 In Use
50090-7480-00 50090-7480 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Dec 20, 2024 In Use
50090-7481-00 50090-7481 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Dec 20, 2024 In Use
70518-4145-02 70518-4145 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 20, 2024 In Use
70518-4245-00 70518-4245 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 20, 2024 In Use
50090-7480-02 50090-7480 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Dec 20, 2024 In Use
00480-3237-51 00480-3237 Lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Dec 19, 2024 In Use
81927-0201-01 81927-0201 Imatinib oral IMKELDI 80.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 19, 2024 In Use
68071-3721-01 68071-3721 PREDNISONE PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec 19, 2024 In Use
72374-0102-01 72374-0102 Filgrastim-txid NYPOZI 480.0 ug/480ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Dec 16, 2024 In Use
72374-0101-01 72374-0101 Filgrastim-txid NYPOZI 300.0 ug/300ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Dec 16, 2024 In Use
00409-0009-25 00409-0009 ONDANSETRON Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec 16, 2024 In Use

Found 11465 results — Export these results